Advertisement

Cancer Immunology, Immunotherapy

, Volume 36, Issue 1, pp 25–30 | Cite as

The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy

  • Andrew Mark Jackson
  • Stephen Prescott
  • Simon John Hawkyard
  • Keith James
  • Geoffrey Chisholm
Original articles

Summary

Bladder cancer cells were stimulated with urine obtained from patients with superficial bladder cancer who had received treatment using intravesical bacillus Calmette-Guérin (BCG). The urine from the first 12 h following each of six BCG instillations was collected and examined for its biological effect. We evaluated effects that had previously been attributed to cytokines detected in the urine of such patients. The modulation of MHC class II antigen and intercellular adhesion molecule-1 (ICAM-1) expression were studied. Using neutralizing polyclonal antibodies to interferon γ and tumour factor α the relative contribution of these molecules to the effects investigated were determined. When cells were stimulated for up to 48 h with first-instillation urine, little effect was seen in any of the parameters investigated. Urine from the sixth instillation, however, proved to be a potent immunomodulatory agent, inducing MHC class II molecule and ICAM-1 expression. Urine from instillations two to five mediated increasing immunomodulatory effects. When sixth-instillation urine samples were treated with neutralizing antibodies to interferon γ prior to their addition to the bladder cancer cells, a marked and significant decrease in their potency was observed. Only in urine from one patient did any immunomodulatory capability remain after antibody treatment. Neutralizing antibodies to tumour necrosis factor α, however, failed to reduce the ability of any patient's urine to induce ICAM-1 expression. When both antibodies were used simultaneously no further decrease in potency was observed. These studies demonstrate for the first time the potential immunomodulatory and cytotoxic effects of urine produced by patients receiving intravesical BCG. Furthermore, in all samples tested, the major immunomodulatory component was shown to be interferon γ. Although tumour necrosis factor α is produced as a result of BCG therapy, this cytokine did not appear to contribute to the parameters investigated. namely the induction of HLA class II antigens, and cell-surface ICAM-1.

Key words

Bladder cancer ICAM-1 MHC class II BCG therapy Interferon γ 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bohle A, Nowc CH, Ulmer AJ, Musehold J, Gerdes J, Hofster A, Flad HD (1990) Elevations of cytokines interleukin-1, interleukin-2 and tumour necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 144: 59PubMedGoogle Scholar
  2. 2.
    Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA (1986) Induction by Il-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherance molecule (ICAM-1). J Exp Med 137: 245Google Scholar
  3. 3.
    El-Demiry MIM, Smith G, Ritchie AWS, James K, Cumming JA, Hargreave TB, Chisholm GD (1987) Local immune response after intravesical Bacille Calmette-Guérin treatment for carcinoma in situ. Br J Urol 60: 543PubMedGoogle Scholar
  4. 4.
    de Fougerolles AR, Springer TA (1992) Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J Exp Med 175: 185PubMedGoogle Scholar
  5. 5.
    Geboers ADH, van Bergen T, Oosterlinck W (1987) Gamma interferon in the therapeutic and prophylactic treatment of superficial bladder cancer. J Urol 137: 276AGoogle Scholar
  6. 6.
    Haaff EO, Catalona WJ, Ratcliffe TL (1987) Detection of interleukin-2 in the urine of patients with superficial bladder tumours after treatment with intravesical BCG. J Urol 136: 970Google Scholar
  7. 7.
    Hawkyard SJ, James K, Prescott S, Jackson AM, Ritchie AWS, Smyth JF, Chisholm GD (1991) The effects of recombinant interferon-gamma on a panel of human bladder cancer cell lines. J Urol 145: 1078PubMedGoogle Scholar
  8. 8.
    Hawkyard SJ, Jackson AM, James K, Prescott S, Smyth JF, Chisholm GD (1992) The inhibitory effects of interferon-gamma on the growth of bladder cancer cell lines. J Urol (in press)Google Scholar
  9. 9.
    Herr HW, Pinsky CM, Whitmore WF, Sorgani PC, Oettgen HF, Melamed MR (1986) Long term effect of intravesical Bacillus Calmette-Guérin on flat carcinoma in situ of the bladder J Urol 135: 265PubMedGoogle Scholar
  10. 10.
    Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD (1992) Expression of adhesion molecules on bladder cancer cells. Modulation by interferon-gamma and tumour necrosis factor-alpha. J Urol (in press)Google Scholar
  11. 11.
    Jackson AM, Alexandrov A, Prescott S, James K, Chisholm GD (1992) Role fo adhesion molecules in lymphokine activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leukocyte function associated antigen-1. Immunology 76, 286–291PubMedGoogle Scholar
  12. 12.
    Janeway CA, Bottomly K, Babich J, Conrad P, Conzen S, Jones B, Kaye J, Katz M, McVay L, Murphy DB, Tite J (1984) Quantitative variation in Ia antigen expression plays a central role in immune regulation. Immunol Today 5: 99Google Scholar
  13. 13.
    Lamm DL (1987) BCG immunotherapy in bladder cancer. In: Urology annual. Appleton and Lange, Norwalk, Conn p 67Google Scholar
  14. 14.
    Larson RS, Springer TA (1990) Structure and function of the leukocyte integrins. Immunol Rev 144: 181Google Scholar
  15. 15.
    Pober JS, Collins T, Gimborne MA, Cotram RS, Gitlin JD, Fiers W, Clayberger C, Krensky AM, Burakoff SJ, Reiss CS (1983) Lymphocytes recognise human vascular endothelial and dermal fibroblast Ia antigens induced by reombinant human interferon. Nature 305: 726PubMedGoogle Scholar
  16. 16.
    Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF (1989) HLA-DR expression by high grade superficial bladder cancer treated by BCG. Br J Urol 63: 264PubMedGoogle Scholar
  17. 17.
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radioimmunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248PubMedGoogle Scholar
  18. 18.
    Ratcliffe TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG mediated antitumour activity. J Urol 137: 155PubMedGoogle Scholar
  19. 19.
    Stauton DE, Dustin ML, Springer TA (1989) Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 339: 61PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Andrew Mark Jackson
    • 1
  • Stephen Prescott
    • 1
  • Simon John Hawkyard
    • 1
  • Keith James
    • 1
  • Geoffrey Chisholm
    • 1
  1. 1.Department of Surgery/Urology (WGH)University of Edinburgh Medical SchoolEdinburghUK

Personalised recommendations